Vanda Pharmaceuticals (VNDA) Non-Current Deffered Revenue (2010 - 2014)

Vanda Pharmaceuticals has reported Non-Current Deffered Revenue for 5 years, with the latest figure at $3.1 million in Q4 2014.

• Quarterly Non-Current Deffered Revenue fell 95.12% year-over-year to $3.1 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $3.1 million (down 95.12% YoY) and the FY2014 annual result came in at $3.1 million, down 95.12% from the prior year.
• Non-Current Deffered Revenue slipped to $3.1 million in Q4 2014 per VNDA's latest filing, from $36.2 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $143.9 million in Q4 2010 and troughed at $461000.0 in Q4 2011.
• A 5-year average of $46.8 million and a median of $19.7 million in 2014 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2011 and 2012: Non-Current Deffered Revenue plunged 99.68% in 2011, then jumped 19482.43% in 2012.
• Over 5 years, Non-Current Deffered Revenue stood at $143.9 million in 2010, then slumped by 99.68% to $461000.0 in 2011, then surged by 19482.43% to $90.3 million in 2012, then declined by 29.67% to $63.5 million in 2013, then slumped by 95.12% to $3.1 million in 2014.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $3.1 million, $36.2 million, and $2.9 million for Q4 2014, Q3 2014, and Q2 2014 respectively.